{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:22:07Z","timestamp":1792081327528,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Eli Lilly and Company"],"award-info":[{"award-number":["Eli Lilly and Company"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11136-024-03829-3","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T18:26:44Z","timestamp":1731522404000},"page":"509-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Psychometric evaluation of the Functional Assessment of chronic illness therapy\u2013fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn\u2019s disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Miguel","family":"Regueiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0666-9804","authenticated-orcid":false,"given":"Sylvia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Stassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane K.","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Clucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"3829_CR1","doi-asserted-by":"publisher","unstructured":"Baumgart, D. C., & Sandborn, W. J. (2012). Crohn\u2019s disease. Lancet, 380(9853), 1590\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(12)60026-9","DOI":"10.1016\/S0140-6736(12)60026-9"},{"issue":"3","key":"3829_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani, D., Danese, S., Peyrin-Biroulet, L., Nikolopoulos, G. K., Lytras, T., & Bonovas, S. (2019). Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology, 157(3), 647\u2013659. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.016","journal-title":"Gastroenterology"},{"issue":"3","key":"3829_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet, L., Panes, J., Sandborn, W. J., Vermeire, S., Danese, S., Feagan, B. G., et al. (2016). Defining disease severity in inflammatory bowel diseases: Current and future directions. Clinical Gastroenterology and Hepatology, 14(3), 348\u2013354. https:\/\/doi.org\/10.1016\/j.cgh.2015.06.001","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"3829_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis, E., Ramos-Goni, J. M., Cuervo, J., Kopylov, U., Barreiro-de Acosta, M., McCartney, S., et al. (2020). A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient, 13(3), 317\u2013325. https:\/\/doi.org\/10.1007\/s40271-019-00407-5","journal-title":"Patient"},{"issue":"1","key":"3829_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2020.18936","volume":"325","author":"K Cushing","year":"2021","unstructured":"Cushing, K., & Higgins, P. D. R. (2021). Management of Crohn disease: A review. Journal of the American Medical Association, 325(1), 69\u201380. https:\/\/doi.org\/10.1001\/jama.2020.18936","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"3829_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11136-022-03233-9","volume":"32","author":"R Williams-Hall","year":"2023","unstructured":"Williams-Hall, R., Trennery, C., Sully, K., Wratten, S., Francis, A., Chandler, D., et al. (2023). A qualitative study to explore the symptoms and impacts of Crohn\u2019s disease and to develop the Crohn\u2019s Disease Diary. Quality of Life Research, 32(1), 209\u2013223. https:\/\/doi.org\/10.1007\/s11136-022-03233-9","journal-title":"Quality of Life Research"},{"issue":"5","key":"3829_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cgh.2021.06.034","volume":"20","author":"A D\u2019Silva","year":"2022","unstructured":"D\u2019Silva, A., Fox, D. E., Nasser, Y., Vallance, J. K., Quinn, R. R., Ronksley, P. E., & Raman, M. (2022). Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: A systematic review with meta-analysis. Clinical Gastroenterology and Hepatology, 20(5), 995\u20131009. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.034","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"8","key":"3829_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cgh.2013.10.019","volume":"12","author":"MD Kappelman","year":"2014","unstructured":"Kappelman, M. D., Long, M. D., Martin, C., DeWalt, D. A., Kinneer, P. M., Chen, W., et al. (2014). Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology, 12(8), 1315\u201323e2. https:\/\/doi.org\/10.1016\/j.cgh.2013.10.019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"3829_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12955-022-01975-1","volume":"20","author":"A Nag","year":"2022","unstructured":"Nag, A., & Romero, B. (2022). Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn\u2019s disease in adults with moderate-to-severe disease. Health and Quality of Life Outcomes, 20(1), 75. https:\/\/doi.org\/10.1186\/s12955-022-01975-1","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"3829_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2036.2010.04347.x","volume":"32","author":"DR van Langenberg","year":"2010","unstructured":"van Langenberg, D. R., & Gibson, P. R. (2010). Systematic review: Fatigue in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 32(2), 131\u2013143. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04347.x","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"12","key":"3829_CR11","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/ibd\/izab007","volume":"27","author":"B Klusmann","year":"2021","unstructured":"Klusmann, B., Fleer, J., Tovote, K. A., Weersma, R. K., van Dullemen, H. M., Dijkstra, G., & Schroevers, M. J. (2021). Trajectories of fatigue in inflammatory bowel disease. Inflammatory Bowel Diseases, 27(12), 1919\u20131930. https:\/\/doi.org\/10.1093\/ibd\/izab007","journal-title":"Inflammatory Bowel Diseases"},{"key":"3829_CR12","doi-asserted-by":"publisher","unstructured":"Farrell, D., McCarthy, G., & Savage, E. (2016). Self-reported symptom burden in individuals with inflammatory bowel disease. J Crohns Colitis, 10(3), 315\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv218","DOI":"10.1093\/ecco-jcc\/jjv218"},{"issue":"5","key":"3829_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s41669-023-00419-w","volume":"7","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus, E. V. Jr., Ananthakrishnan, A. N., Lee, W. J., Gonzalez, Y. S., Fitzgerald, K. A., Wallace, K., et al. (2023). Content validity and psychometric evaluation of the Functional Assessment of Chronic illness therapy-fatigue (FACIT-Fatigue) in patients with Crohn\u2019s disease and ulcerative colitis. Pharmacoecon Open, 7(5), 823\u2013840. https:\/\/doi.org\/10.1007\/s41669-023-00419-w","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"3829_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s41687-023-00612-9","volume":"7","author":"M Regueiro","year":"2023","unstructured":"Regueiro, M., Delbecque, L., Hunter, T., Stassek, L., Harding, G., & Lewis, J. (2023). Experience and measurement of fatigue in adults with Crohn\u2019s disease: Results from qualitative interviews and a longitudinal 2-week daily diary pilot study. J Patient Rep Outcomes, 7(1), 75. https:\/\/doi.org\/10.1186\/s41687-023-00612-9","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"3829_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3748\/wjg.v18.i5.445","volume":"18","author":"LP Jelsness-Jorgensen","year":"2012","unstructured":"Jelsness-Jorgensen, L. P., Bernklev, T., Henriksen, M., Torp, R., & Moum, B. (2012). Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease. World Journal of Gastroenterology, 18(5), 445\u2013452. https:\/\/doi.org\/10.3748\/wjg.v18.i5.445","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"3829_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12325-022-02364-2","volume":"40","author":"M Regueiro","year":"2023","unstructured":"Regueiro, M., Hunter, T., Lukanova, R., Shan, M., Wild, R., Knight, H., et al. (2023). Burden of fatigue among patients with ulcerative colitis and Crohn\u2019s disease: Results from a global survey of patients and gastroenterologists. Adv Ther, 40(2), 474\u2013488. https:\/\/doi.org\/10.1007\/s12325-022-02364-2","journal-title":"Adv Ther"},{"key":"3829_CR17","doi-asserted-by":"publisher","unstructured":"Stroie, T., Preda, C., Meianu, C., Istratescu, D., Manuc, M., Croitoru, A., et al. (2023). Fatigue is associated with anxiety and lower health-related quality of life in patients with inflammatory bowel disease in remission. Medicina (Kaunas), 59(3). https:\/\/doi.org\/10.3390\/medicina59030532","DOI":"10.3390\/medicina59030532"},{"issue":"11\u201312","key":"3829_CR18","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","volume":"34","author":"A Tinsley","year":"2011","unstructured":"Tinsley, A., Macklin, E. A., Korzenik, J. R., & Sands, B. E. (2011). Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 34(11\u201312), 1328\u20131336. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04871.x","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"3829_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.crohns.2014.01.004","volume":"8","author":"W Czuber-Dochan","year":"2014","unstructured":"Czuber-Dochan, W., Norton, C., Bredin, F., Darvell, M., Nathan, I., & Terry, H. (2014). Healthcare professionals\u2019 perceptions of fatigue experienced by people with IBD. J Crohns Colitis, 8(8), 835\u2013844. https:\/\/doi.org\/10.1016\/j.crohns.2014.01.004","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3829_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12325-019-01151-w","volume":"37","author":"A Nocerino","year":"2020","unstructured":"Nocerino, A., Nguyen, A., Agrawal, M., Mone, A., Lakhani, K., & Swaminath, A. (2020). Fatigue in inflammatory bowel diseases: Etiologies and management. Adv Ther, 37(1), 97\u2013112. https:\/\/doi.org\/10.1007\/s12325-019-01151-w","journal-title":"Adv Ther"},{"key":"3829_CR21","unstructured":"FACIT (2007). FACIT Fatigue Scale (Version 4). Retrieved from: https:\/\/www.facit.org\/_files\/ugd\/626819_3f37469b87fc4f779aa9e31790c8c2f2.pdf"},{"issue":"10S","key":"3829_CR22","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.14309\/01.ajg.0000859976.41101.2c","volume":"117","author":"M Regueiro","year":"2022","unstructured":"Regueiro, M., Fischer, M., Rubin, D. T., Hibi, T., Bossuyt, P., & Juillerat, P. (2022). S834 improvement in fatigue with mirikizumab therapy is associated with clinical remission and pain improvements but not with endoscopic response in patients with moderately-to-severely active Crohn\u2019s Disease. Official Journal of the American College of Gastroenterology, 117(10S), e602\u2013e603. https:\/\/doi.org\/10.14309\/01.ajg.0000859976.41101.2c","journal-title":"Official Journal of the American College of Gastroenterology"},{"key":"3829_CR23","unstructured":"US Food and Drug Administration (2009). Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. Retrieved from https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"3829_CR24","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1182\/blood-2023-174965","volume":"142","author":"K Scippa","year":"2023","unstructured":"Scippa, K., Mangrum, R., Martin, S., Cueto, D., Bryant, A., Schantz, K., & Pease, S. (2023). Establishing content validity of the FACIT-Fatigue scale in patients living with warm autoimmune hemolytic anemia: Results from qualitative interview studies. Blood, 142, 3753. https:\/\/doi.org\/10.1182\/blood-2023-174965","journal-title":"Blood"},{"issue":"3","key":"3829_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","volume":"96","author":"G Guyatt","year":"1989","unstructured":"Guyatt, G., Mitchell, A., Irvine, E. J., Singer, J., Williams, N., Goodacre, R., & Tompkins, C. (1989). A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 96(3), 804\u2013810. https:\/\/doi.org\/10.1016\/S0016-5085(89)80080-0","journal-title":"Gastroenterology"},{"issue":"4","key":"3829_CR26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","volume":"14","author":"EJ Irvine","year":"2008","unstructured":"Irvine, E. J. (2008). Quality of life of patients with ulcerative colitis: Past, present, and future. Inflammatory Bowel Diseases, 14(4), 554\u2013565. https:\/\/doi.org\/10.1002\/ibd.20301","journal-title":"Inflammatory Bowel Diseases"},{"key":"3829_CR27","doi-asserted-by":"crossref","unstructured":"Irvine, E. J., Zhou, Q., & Thompson, A. K. (1996). The short inflammatory bowel disease questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol, 91(8), 1571\u20131578.","DOI":"10.1037\/t84172-000"},{"issue":"8","key":"3829_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00520-011-1148-2","volume":"19","author":"LF Brown","year":"2011","unstructured":"Brown, L. F., Kroenke, K., Theobald, D. E., & Wu, J. (2011). Comparison of SF-36 vitality scale and fatigue Symptom Inventory in assessing cancer-related fatigue. Supportive Care in Cancer, 19(8), 1255\u20131259. https:\/\/doi.org\/10.1007\/s00520-011-1148-2","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"3829_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976). Development of a Crohn\u2019s Disease Activity Index. Gastroenterology, 70(3), 439\u2013444. https:\/\/doi.org\/10.1016\/s0016-5085(76)80163-1","journal-title":"Gastroenterology"},{"issue":"10066","key":"3829_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., et al. (2017). Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet, 389(10066), 266\u2013275. https:\/\/doi.org\/10.1016\/s0140-6736(16)32537-5","journal-title":"Lancet"},{"issue":"9","key":"3829_CR31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/apt.16805","volume":"55","author":"ECL Wong","year":"2022","unstructured":"Wong, E. C. L., Dulai, P. S., Marshall, J. K., Jairath, V., Reinisch, W., & Narula, N. (2022). Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn\u2019s disease. Alimentary Pharmacology & Therapeutics, 55(9), 1151\u20131159. https:\/\/doi.org\/10.1111\/apt.16805","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"3829_CR32","doi-asserted-by":"publisher","unstructured":"Abbass, M., Cepek, J., Parker, C. E., Nguyen, T. M., MacDonald, J. K., Feagan, B. G. (2019). Adalimumab for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev, 2019(11). https:\/\/doi.org\/10.1002\/14651858.CD012878.pub2","DOI":"10.1002\/14651858.CD012878.pub2"},{"issue":"1","key":"3829_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12876-022-02347-1","volume":"22","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., et al. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. Bmc Gastroenterology, 22(1), 291. https:\/\/doi.org\/10.1186\/s12876-022-02347-1","journal-title":"Bmc Gastroenterology"},{"issue":"4","key":"3829_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno, M., D\u2019Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., et al. (2004). Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD. Gastrointestinal Endoscopy, 60(4), 505\u2013512. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4","journal-title":"Gastrointestinal Endoscopy"},{"key":"3829_CR35","doi-asserted-by":"crossref","unstructured":"Hays, R., & Revicki, D. (2005). Reliability and validity (including responsiveness). In P. Fayers, & R. Hays (Eds.), Assessing quality of life in clinical trials. Oxford University Press.","DOI":"10.1093\/oso\/9780198527695.003.0003"},{"key":"3829_CR36","unstructured":"Hinkle, D. E., Wiersma, W., & Jurs, S. G. (2022). Applied statistics for the behavioral sciences. 5th ed."},{"key":"3829_CR37","unstructured":"Scheff\u00e9, H. (1959). The analysis of variance. Wiley."},{"issue":"9","key":"3829_CR38","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","volume":"29","author":"G Coteur","year":"2009","unstructured":"Coteur, G., Feagan, B., Keininger, D. L., & Kosinski, M. (2009). Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn\u2019s disease. Alimentary Pharmacology & Therapeutics, 29(9), 1032\u20131041. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.03966.x","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"5","key":"3829_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0961203313476360","volume":"22","author":"M Kosinski","year":"2013","unstructured":"Kosinski, M., Gajria, K., Fernandes, A. W., & Cella, D. (2013). Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus, 22(5), 422\u2013430. https:\/\/doi.org\/10.1177\/0961203313476360","journal-title":"Lupus"},{"key":"3829_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae166","author":"M Regueiro","year":"2024","unstructured":"Regueiro, M., Fischer, M., Bossuyt, P., McGinnis, K., Protic, M., Gibble, H., T., et al. (2024). Mirikizumab sustained impact on fatigue in patients with moderately to severely active Crohn\u2019s disease in the phase 2 AMAG study. Inflammatory Bowel Diseases. https:\/\/doi.org\/10.1093\/ibd\/izae166","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Supplement_1","key":"3829_CR41","doi-asserted-by":"publisher","first-page":"i560","DOI":"10.1093\/ecco-jcc\/jjac190.0564","volume":"17","author":"S Ghosh","year":"2023","unstructured":"Ghosh, S., Feagan, B., Parra, R. S., Lopes, S., Steinlauf, A., Kakuta, Y., et al. (2023). P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn\u2019s disease: Results from induction and maintenance phase 3 trials. Journal of Crohn\u2019s and Colitis, 17(Supplement_1), i560\u2013i562. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.0564","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"3829_CR42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/apt.17242","volume":"57","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet, L., Ghosh, S., Lee, S. D., Lee, W. J., Griffith, J., Wallace, K., et al. (2023). Effect of risankizumab on health-related quality of life in patients with Crohn\u2019s disease: Results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Alimentary Pharmacology & Therapeutics, 57(5), 496\u2013508. https:\/\/doi.org\/10.1111\/apt.17242","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"3829_CR43","unstructured":"National Library of Medicine (2023). NCT03926130. A study of mirikizumab (LY3074828) in participants with Crohn\u2019s Disease (VIVID-1). Retrieved from: https:\/\/www.clinicaltrials.gov\/study\/NCT03926130"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03829-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03829-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03829-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T01:40:54Z","timestamp":1740620454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03829-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03829-3","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"31 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was compliant with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical guidelines and the International Conference on Harmonization guidelines on Good Clinical Practice. All informed consent forms and protocols were approved by appropriate ethical review boards before initiation of the study. All participants provided written informed consent before any study procedures were performed and before study drug administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No additional consent was required for the analyses described.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MR serves on advisory boards for AbbVie, Janssen, UCB, Takeda, Pfizer, BMS, Organon, Amgen, Genentech, Gilead, Salix, Prometheus, Eli Lilly and Company, TARGET Pharma Solutions, and Trellus. SS, AV, and FD are employees and shareholders of Eli Lilly and Company. XZ is an employee of Syneos Health, which received funding from Eli Lilly and Company in connection with this study. LS, AKK, and CC are employees of Evidera, which received funding from Eli Lilly and Company in connection with this study. VJ has received fees or grant and\/or research support and\/or served as a consultant and\/or speaker for AbbVie, Alimentiv, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Ferring Pharmaceuticals, Flagship Pioneering, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Metacrine, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx Biosciences, and Vividion Therapeutics.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}